Researchers at the University of Pittsburgh School of Medicine have cracked a longstanding puzzle about how melanoma tumors essentially become immortal, discovering that two genetic mutations working together give cancer cells the ability to divide endlessly and grow unchecked.
The finding, published this week in Science, identifies a combination of genetic changes in the telomere maintenance system that allows melanoma cells to dramatically extend their lifespan. The breakthrough could reshape how scientists approach treating one of the deadliest cancers and points toward new therapeutic targets.
The problem researchers were trying to solve centered on telomeres, the protective caps at the ends of chromosomes that regulate how many times a cell can divide. Every time a healthy cell divides, its telomeres shorten. Eventually they become so short that the cell stops dividing and dies. This natural limit is a powerful anticancer defense.
Melanoma tumors, however, maintain exceptionally long telomeres compared to most other cancers. That fact has puzzled scientists for years. An enzyme called telomerase can lengthen telomeres, and about 75 percent of melanoma tumors carry mutations in the TERT gene that boost telomerase production. Yet when researchers introduced those same TERT mutations into normal melanocytes in the lab, they could not recreate the unusually long telomeres seen in actual melanoma tumors. Something crucial was missing.
That missing piece turned out to be a second genetic mutation in a protein called TPP1, which binds to telomeres and regulates telomerase activity. Pattra Chun-on, an internist pursuing her Ph.D. in Jonathan Alder's lab at Pitt, discovered that TPP1 mutations were far more common in melanoma than previously recognized. The mutations occurred in the promoter region of the TPP1 gene and increased production of the protein.
When Chun-on introduced both the mutated TERT and mutated TPP1 into cells, something remarkable happened. The two proteins working together produced the exceptionally long telomeres that characterize melanoma tumors. The missing link had been identified.
"We did something that was, in essence, obvious based on previous basic research and connected back to something that is happening in patients," Alder said. The finding emerged from earlier work by his lab that had spotted TPP1 mutations while analyzing cancer databases, but the significance had not been fully appreciated until Chun-on connected the dots.
The implications reach beyond basic science. The discovery describes a cancer-specific telomere maintenance system that exists in melanoma tumors but not in healthy cells. That specificity is crucial for drug development, since it means potential therapies could target this system in cancer cells while leaving normal telomeres untouched.
The research involved collaboration with scientists at UC Santa Cruz, Johns Hopkins University, and other institutions. The work was funded by National Institutes of Health grants.
Author Jessica Williams: "This is the kind of mechanistic detective work that finally gives oncologists an actual bullseye for melanoma treatment, not just a general idea about why these tumors are so hard to kill."
Comments